Xenon Pharmaceuticals Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
XENE$41.39+2.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Shareholders’ Equity
(Expressed in thousands of U.S. dollars except share amounts)
| Common shares · Additionalpaid-incapital · Accumulateddeficit · Accumulatedother comprehensiveincome (loss) · Totalshareholders'equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2024 | 76,416,086 | $1,456,836 | $199,149 | $(899,470) | $(1,612) | $754,903 |
| Net loss for the period | — | — | — | (65,047) | — | (65,047) |
| Stock-based compensation expense | — | — | 12,174 | — | — | 12,174 |
| Issuance of common shares pursuant to equity incentive plans | 170,273 | 4,014 | (2,863) | — | — | 1,151 |
| Other comprehensive income | — | — | — | — | 776 | 776 |
| Balance as of March 31, 2025 | 76,586,359 | $1,460,850 | $208,460 | $(964,517) | $(836) | $703,957 |
| Net loss for the period | — | — | — | (84,706) | — | (84,706) |
| Stock-based compensation expense | — | — | 13,713 | — | — | 13,713 |
| Issuance of common shares pursuant to equity incentive plans | 353,452 | 8,346 | (8,281) | — | — | 65 |
| Other comprehensive income | — | — | — | — | 949 | 949 |
| Balance as of June 30, 2025 | 76,939,811 | $1,469,196 | $213,892 | $(1,049,223) | $113 | $633,978 |
| Balance as of December 31, 2025 | 80,010,790 | $1,598,571 | $228,234 | $(1,245,380) | $335 | $581,760 |
|---|---|---|---|---|---|---|
| Net loss for the period | — | — | — | (102,302) | — | (102,302) |
| Issuance of common shares and pre-funded warrants, net | 15,370,962 | 790,198 | 47,328 | — | — | 837,526 |
| Exercise of pre-funded warrants | 118,980 | 3,296 | (3,296) | — | — | — |
| Stock-based compensation expense | — | — | 16,894 | — | — | 16,894 |
| Issuance of common shares pursuant to equity incentive plans | 1,123,391 | 29,768 | (24,281) | — | — | 5,487 |
| Other comprehensive loss | — | — | — | — | (1,546) | (1,546) |
| Balance as of March 31, 2026 | 96,624,123 | $2,421,833 | $264,879 | $(1,347,682) | $(1,211) | $1,337,819 |
| Net loss for the period | — | — | — | (110,736) | — | (110,736) |
| Stock-based compensation expense | — | — | 16,732 | — | — | 16,732 |
| Issuance of common shares pursuant to equity incentive plans | 128,761 | 4,786 | (4,760) | — | — | 26 |
| Other comprehensive loss | — | — | — | — | (1,445) | (1,445) |
| Balance as of June 30, 2026 | 96,752,884 | $2,426,619 | $276,851 | $(1,458,418) | $(2,656) | $1,242,396 |
-5-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.